Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-21.49	-26.27	-43.02	-20.65	-11.71
Depreciation & Amortization	0.69	0.73	0.87	2.11	3.13
Share-Based Compensation	4.64	4.29	3.72	2.35	3.58
Other Operating Activities	-12.41	22.32	14.86	-3.56	-26.95
Operating Cash Flow	-28.57	1.06	-23.56	-19.75	-31.95
Capital Expenditures	-0.67	-0.41	-0.34	-0.04	-0.36
Acquisitions	0	0	10.09	13.06	17.33
Change in Investments	47.12	-45.75	0	0	0
Other Investing Activities	-	-	-	0.02	-0.02
Investing Cash Flow	46.45	-46.16	9.75	13.04	16.96
Share Issuance / Repurchase	6.59	0.13	30.81	5.1	-0.01
Debt Issued / Paid	-0.05	-0.03	-0.02	25.12	-0.1
Other Financing Activities	-0.11	1.53	6.14	-0.36	0.72
Financing Cash Flow	6.42	1.63	36.93	29.87	0.62
Exchange Rate Effect	-0.25	-0.87	-0.02	-0.06	0.07
Net Cash Flow	24.06	-44.34	23.09	23.09	-14.3
Free Cash Flow	-29.24	0.65	-23.9	-19.79	-32.31
Free Cash Flow Margin	-326.89%	4.39%	-550.59%	-1084.01%	-919.06%
Free Cash Flow Per Share	-0.17	0.00	-0.14	-0.13	-0.22

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).